Prescription medicine
Ixekizumab Brand names: Taltz
Ixekizumab (Taltz) is a prescription medicine with an FDA approval on record since 2016. No generic is listed; pharmacies paid $7,370.72 per mL (Taltz 80 mg/mL autoinjector) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the ixekizumab FDA label on DailyMed (effective January 22, 2026, Eli Lilly and Company); the BLA 125521 record on Drugs@FDA; every ixekizumab label on DailyMed.
Highlights of the record
FDA label of January 22, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Forms and strengths
- 20 mg/.25ml
- 40 mg/.5ml
- 80 mg/ml
Injection (solution).
On the market
- Earliest approval on file
- March 22, 2016 Taltz, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $7,370.72 per mL Taltz 80 mg/mL autoinjector
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 36,780 through July 30, 2026
What is ixekizumab used for?
From the label: indications and usageTALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. […]
Conditions named in the indications of ixekizumab's FDA labels, with every medicine labeled for each:
From other ixekizumab labelsPsoriasis: Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
FDA pharmacologic class: Interleukin-17A Antagonist.
Source: FDA drug label (TALTZ), Eli Lilly and Company, effective January 22, 2026 (SPL set ac96658a-d7dc-4c7c-8928-2adcdf4318b2), via openFDA; the full label on DailyMed
What does the patient leaflet for ixekizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about TALTZ?TALTZ is a medicine that affects your immune system. TALTZ may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections while taking TALTZ, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Your healthcare provider should check you for TB before you start treatment with TALTZ. Your healthcare provider may treat you with medicine for TB before you begin treatment with TALTZ if you have a past history of TB or have TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TALTZ. Before starting TALTZ, tell your healthcare provider if you: are being treated for an infection have an infection that does not go away or that keeps coming back have TB or have been in close contact with someone with TB think you have an infection or have symptoms of an infection such as: fever, sweats, or chills muscle aches cough shortness of breath blood in your phlegm (mucus) weight loss warm, red, or painful skin or sores on your body diarrhea or stomach pain burning when you urinate or urinate more often than normal After starting TALTZ, call your healthcare provider right away if you have any of the symptoms of infection listed above. Do not use TALTZ if you have any symptoms of infection unless you are instructed to by your healthcare provider. See “ What are the possible side effects of TALTZ? ” for more information about side effects.
From the patient leaflet: How should I store TALTZ?Protect TALTZ from light. Store TALTZ in the refrigerator between 36°F to 46°F (2°C to 8°C). If needed, you or a caregiver may store TALTZ at room temperature up to 86°F (30°C) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator. Throw away TALTZ if it is not used within 5 days at room temperature. Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton. For the 2 or 3 autoinjector pack, remove a single autoinjector at a time leaving the remaining autoinjector(s) in the original carton in the refrigerator. Make sure the unrefrigerated TALTZ is protected from light. Do not freeze TALTZ. Do not use if TALTZ has been frozen. Do not shake TALTZ. Keep TALTZ and all medicines out of the reach of children.
Source: FDA drug label (TALTZ), Eli Lilly and Company, effective January 22, 2026 (SPL set ac96658a-d7dc-4c7c-8928-2adcdf4318b2), via openFDA; the full label on DailyMed
Is there a generic for ixekizumab (Taltz)?
No generic ixekizumab is approved (Drugs@FDA, October 8, 2026).
- 2016 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ixekizumab (Taltz)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $7,370.72 per mL (Taltz 80 mg/mL autoinjector), up 5% from $6,998.18 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Taltz 80 mg/mL autoinjector (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Taltz 80 mg/mL autoinjector | Brand | $7,370.72 per mL | n/a | +5% |
| Taltz 80 mg/mL autoinjector (2-pack) | Brand | $7,435.87 per mL | n/a | +5% |
| Taltz 80 mg/mL autoinjector (3-pack) | Brand | $7,388.22 per mL | n/a | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for ixekizumab?
The FDA Adverse Event Reporting System holds 36,780 reports that list ixekizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 547 are coded as a death and 2,990 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ixekizumab?
7 other medicines are given the same way (subcutaneous) and in the same FDA class as ixekizumab or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Secukinumab | Psoriasis | none listed | $3,946.35 per mL 300 mg dose/2 pens (150 mg/pen) | No current entry |
| Adalimumab-ryvk | Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | A presentation being discontinued |
| Risankizumab | Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No current entry |
| Bimekizumab | Psoriasis | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No current entry |
| Spesolimab | Psoriasis | none listed | n/a | No current entry |
| Brodalumab | Psoriasis | none listed | n/a | No current entry |
| Tildrakizumab | Psoriasis | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as ixekizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to ixekizumab
- 7 medicines for the same use
- Other interleukin-17a antagonists
- the pharmacologic class, with prices and generics
- Ixekizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other